+91 80 2808 2808
Biocon  /  Businesses  /  Biosimilars  /  Board of Directors  /  Daniel Bradbury

Daniel Bradbury

Independent Director

Daniel Bradbury

Independent Director

Year of birth: 1961
Nationality: U.S.

Professional Experience

  • Executive Chairman, former CEO and Co-Founder of Equillium Inc., a company developing products to treat severe autoimmune and inflammatory disorders
  • Managing Member, BioBrit LLC
  • Member, Board of Trustees, Keck Graduate Institute, U.S.
  • Director, Intercept Pharmaceuticals and several private companies and philanthropic organizations
  • Board Chairman, Castle Biosciences Inc & Biolinq
  • Member, Advisory Council, Rady School of Management, San Diego, U.S.
  • Life sciences executive with over 38 years of experience in creating and implementing strategies and transforming businesses
  • Former CEO, Amylin Pharmaceuticals, a leading metabolic disease company, acquired by Bristol Myers Squibb in 2012


  • Recipient of Director of the Year Award from Corporate Directors Forum (2012)
  • EY’s Entrepreneur of the Year Finalist (2012)


  • International Executive Program, INSEAD, France
  • Diploma in Management Studies, Harrow and Ealing Colleges of Higher Education, UK
  • Bachelor of Pharmacy, Nottingham University, UK
Leaving the Biocon site!

You are now leaving the Biocon website for a Biocon affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree >>